What if…you could join an organization that creates, resources, and builds life sciences companies that invent breakthrough technologies in order to transform healthcare and sustainability?

FL54 is a privately held, early stage biotechnology company creating an unprecedented drug discovery platform around transporter proteins to discover novel therapeutics. As the molecular gateways of our bodies, transporters are responsible for the flux of all biomolecules into and out of all cells and organelles. As a generally untapped but druggable class of proteins, transporters have been ignored because they are notoriously difficult to work with. FL54 is developing novel biological and technological solutions for transporter biology to treat a broad range of diseases such as metabolic disease, immunological disease, CNS disorders, and oncology.

FL54 Inc is one of the latest companies founded through Flagship Pioneering’s venture creation engine, where companies such as Moderna Therapeutics, Rubius Therapeutics, and Evelo Therapeutics were conceived and created. Since Flagship’s founding in 2000, the firm has originated and fostered the development of nearly 100 scientific ventures resulting in $19+ billion in aggregate value, 500+ issued patents, and more than 50 clinical trials for novel therapeutic agents.

Position Summary:

We are seeking an Associate Director of Discovery Biology to join the team to develop and advance our programs from early development to proof-of-concept and beyond. The successful candidate is a confident leader with significant prior success in preclinical stage program development and scientific leadership for therapeutic programs in the biotechnology industry. This is an exciting and interdisciplinary role for a highly qualified and motivated individual. We are looking for an enthusiastic, innovative scientist with a passion for bringing novel medicines to patients. S(he) will be comfortable working in and contributing to a very dynamic and cross-functional team environment. The applicant will be part of a fast-paced drug discovery team.

Key Responsibilities:

  • Develop, oversee and direct the therapeutic indication strategy in selected disease areas
  • Design, plan, and execute human cell-based phenotypic screens to identify novel targets
  • Design, plan, and execute human cell-based assays and in vivo experiments to model human disease for target validation and mechanism of action
  • Manage the scientific and operational aspects of the program(s), including implementation, development of program timelines, and monitoring of key milestones and decision points
  • Build, lead and manage a high-performing group of talented scientists
  • Perform research and development in collaboration with other functions in projects pertaining to a range of potential indications
  • Communicate, as appropriate, efforts and progress to internal and external parties

Minimum Qualifications:

  • Ph.D. with 6+ years of relevant post-Ph.D. experience in Biotech/Pharma
  • Successful track record of target selection and validation
  • Demonstrated experience in the discovery and preclinical development of therapeutics targeting membrane proteins (Transporters, ion channels, GPCRs)
  • Broad experience in multiple therapeutic areas (e.g. metabolism, immunology, cardiology, oncology, neurology, or orphan diseases)
  • Experience designing and validating novel cell-based assays, phenotypic screens, in vivo disease models to evaluate potential new targets
  • Prior experience working with or leading collaborations with external academic, biotechnology, and contract research organizations
  • Experience in mentoring and/or leading Ph.D. level and non-Ph.D. level scientists
  • Ability to organize and communicate complex data sets in a clear and concise manner to key stakeholders from diverse backgrounds


More About Flagship Pioneering

We are creative optimists and we would love for you to consider joining our team!  See all our open opportunities across Flagship Pioneering’s Ecosystem!

Flagship Pioneering conceives, creates, resources, and develops first-in-category life sciences companies to transform human health and sustainability. Since its launch in 2000, the firm has applied a unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in over $34 billion in aggregate value. To date, Flagship is backed by more than $4.4 billion of aggregate capital commitments, of which over $1.9 billion has been deployed toward the founding and growth of its pioneering companies alongside more than $10 billion of follow-on investments from other institutions. The current Flagship ecosystem comprises 41 transformative companies, including:  Axcella Health (NASDAQ: AXLA), Denali Therapeutics (NASDAQ: DNLI), Evelo Biosciences (NASDAQ: EVLO),  Foghorn Therapeutics, Indigo Ag, Kaleido Biosciences (NASDAQ: KLDO), Moderna (NASDAQ: MRNA), Rubius Therapeutics (NASDAQ: RUBY), Sana Biotechnology, Seres Therapeutics (NASDAQ: MCRB), and Syros Pharmaceuticals (NASDAQ: SYRS).

We believe pioneering is best done by teams, and that it is a process that can be taught, learned, and replicated.  Learn more about our Company Creation Model.

Can Breakthrough Innovations Be Made Systematically? A Conversation With Noubar Afeyan, Flagship Pioneering’s CEO.

Recruitment & Staffing Agencies:  Flagship Pioneering and its affiliated Flagship Lab companies (collectively, “FSP”) do not accept unsolicited resumes from any source other than candidates.  The submission of unsolicited resumes by recruitment or staffing agencies to FSP or its employees is strictly prohibited unless contacted directly by Flagship Pioneering’s internal Talent Acquisition team.   Any resume submitted by an agency in the absence of a signed agreement will automatically become the property of FSP, and FSP will not owe any referral or other fees with respect thereto.

Apply for this Job

* Required